SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Illumina (ILMN) Optics for Genomics
ILMN 123.54+24.8%Oct 31 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: idos7/1/2008 2:17:09 PM
   of 276
 
Nice contract for ILMN:

biz.yahoo.com

The Wellcome Trust Case Control Consortium (WTCCC) Selects Illumina Infinium High-Density (HD) DNA Analysis Products to Study 90,000 Samples

Tuesday July 1, 6:00 am ET

SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN - News) today announced that researchers participating in a new initiative funded by the Wellcome Trust selected Illumina’s Infinium HD BeadChips to analyze 90,000 DNA samples. This new initiative aims to decipher the molecular basis of human disease and includes participation from leading research groups around the globe. Together, researchers at the Wellcome Trust Case Control Consortium 2 (WTCCC2) and 12 independent consortia will collect more than 120,000 DNA samples and analyze them for both single nucleotide polymorphisms (SNPs) and copy number variants (CNVs). This new series of genome-wide association studies are collectively the world’s largest genetic research initiative conducted to date, and is expected to uncover genetic variants linked to many diseases such as multiple sclerosis, schizophrenia, and asthma. In addition to 90,000 samples collected from study participants, 6,000 control samples will be collected and analyzed using Illumina’s Infinium HD Human1M-Duo BeadChip.
snip
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext